CA1331563C
(fr)
*
|
1987-08-03 |
1994-08-23 |
Gaylen M. Zentner |
Systeme de liberation controlee de medicaments avec modulation de type donnan par des resines chargees insolubles
|
US5108756A
(en)
*
|
1989-01-12 |
1992-04-28 |
Pfizer Inc. |
Dispensing devices powered by lyotropic liquid crystals
|
US5030452A
(en)
*
|
1989-01-12 |
1991-07-09 |
Pfizer Inc. |
Dispensing devices powered by lyotropic liquid crystals
|
DD295760A5
(de)
*
|
1989-01-31 |
1991-11-14 |
Martin-Luther-Universitaet Halle Wittenberg,De |
Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
|
DE3932987A1
(de)
*
|
1989-10-03 |
1991-04-11 |
Int Pharma Agentur |
System fuer die kontrollierte freisetzung von wirkstoffen und verfahren zu seiner herstellung
|
EP0408496A3
(en)
*
|
1989-07-12 |
1992-07-01 |
Ciba-Geigy Ag |
Solid dosage form for pharmaceutical substances
|
US5120548A
(en)
*
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
US5192550A
(en)
*
|
1990-05-07 |
1993-03-09 |
Alza Corporation |
Dosage form for treating central nervous system disorders
|
US5221536A
(en)
|
1990-05-07 |
1993-06-22 |
Alza Corporation |
Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
|
US5326570A
(en)
*
|
1991-07-23 |
1994-07-05 |
Pharmavene, Inc. |
Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
|
US5327977A
(en)
*
|
1992-12-14 |
1994-07-12 |
Anthony Lukashuk |
Weeder with hollow tines
|
US6129930A
(en)
|
1993-09-20 |
2000-10-10 |
Bova; David J. |
Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
|
US6080428A
(en)
|
1993-09-20 |
2000-06-27 |
Bova; David J. |
Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
|
US6746691B2
(en)
|
1993-09-20 |
2004-06-08 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
|
US6818229B1
(en)
|
1993-09-20 |
2004-11-16 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia
|
US6676967B1
(en)
*
|
1993-09-20 |
2004-01-13 |
Kos Pharmaceuticals, Inc. |
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
|
US20060263428A1
(en)
*
|
1993-09-20 |
2006-11-23 |
Eugenio Cefali |
Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
|
ZA953078B
(en)
*
|
1994-04-28 |
1996-01-05 |
Alza Corp |
Effective therapy for epilepsies
|
US6348469B1
(en)
|
1995-04-14 |
2002-02-19 |
Pharma Pass Llc |
Solid compositions containing glipizide and polyethylene oxide
|
US5654005A
(en)
*
|
1995-06-07 |
1997-08-05 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation having a preformed passageway
|
DE19531684A1
(de)
*
|
1995-08-29 |
1997-03-06 |
Bayer Ag |
Verfahren zur Herstellung von Arzneimittelzubereitungen mit kontrollierter Freisetzung
|
ES2255103T3
(es)
*
|
1996-10-25 |
2006-06-16 |
Shire Laboratories Inc. |
Sistema osmotico de administracion de dosis en forma soluble.
|
US6361796B1
(en)
|
1996-10-25 |
2002-03-26 |
Shire Laboratories, Inc. |
Soluble form osmotic dose delivery system
|
SI1017392T1
(en)
|
1997-09-25 |
2002-12-31 |
Bayer Aktiengesellschaft |
Medicament formulation with a controlled release of an active agent
|
DE19747261A1
(de)
*
|
1997-10-25 |
1999-04-29 |
Bayer Ag |
Osmotisches Arzneimittelfreisetzungssystem
|
HUP9902351A3
(en)
*
|
1998-07-22 |
2001-01-29 |
Pharma Pass L L C Irvine |
Solid compositions containing metoprolol and process for producing the same
|
US6706283B1
(en)
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
KR100647901B1
(ko)
*
|
1999-07-09 |
2006-11-17 |
보령제약 주식회사 |
세파클러-함유 서방성 약제조성물 및 그의 제조방법
|
JP2003518487A
(ja)
|
1999-12-23 |
2003-06-10 |
ファイザー・プロダクツ・インク |
ヒドロゲル駆動型積層薬物製剤
|
CA2395333C
(fr)
*
|
1999-12-23 |
2009-01-13 |
Pfizer Products Inc. |
Forme de dosage de medicament entraine par un hydrogel
|
WO2001091716A1
(fr)
*
|
2000-05-30 |
2001-12-06 |
Add Advanced Drug Delivery Technologies Ag |
Systeme therapeutique par voie orale comportant du glipizide
|
IN190699B
(fr)
*
|
2001-02-02 |
2003-08-16 |
Sun Pharmaceutical Ind Ltd |
|
GB0209265D0
(en)
*
|
2002-04-23 |
2002-06-05 |
Novartis Ag |
Organic compounds
|
AU2003224358A1
(en)
*
|
2002-05-06 |
2003-11-17 |
Ranbaxy Laboratories Limited |
Monocompartment osmotic controlled drug delivery system
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
US20060286169A1
(en)
*
|
2003-02-13 |
2006-12-21 |
Phares Pharmaceutical Research N.V. |
Lipophilic compositions
|
US8075872B2
(en)
*
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
DE102004020220A1
(de)
*
|
2004-04-22 |
2005-11-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
US20070048228A1
(en)
*
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
DE102005005446A1
(de)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
ES2407143T3
(es)
*
|
2003-08-06 |
2013-06-11 |
Grünenthal GmbH |
Forma de dosificación protegida contra un posible abuso
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
DE102004032051A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
US7611728B2
(en)
*
|
2003-09-05 |
2009-11-03 |
Supernus Pharmaceuticals, Inc. |
Osmotic delivery of therapeutic compounds by solubility enhancement
|
DE102004023069A1
(de)
|
2004-05-11 |
2005-12-08 |
Bayer Healthcare Ag |
Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
|
DE102004032103A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
AR053986A1
(es)
|
2004-12-03 |
2007-05-30 |
Osmotica Pharmaceutical Argent |
Dispositivo osmotico que contiene amantadina y una sal osmotica
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
EP1690540A1
(fr)
*
|
2005-02-15 |
2006-08-16 |
Neuro3D |
Composition comprenant l'ocapéridone
|
US8858993B2
(en)
|
2005-07-25 |
2014-10-14 |
Metrics, Inc. |
Coated tablet with zero-order or near zero-order release kinetics
|
US8778395B2
(en)
|
2005-08-11 |
2014-07-15 |
Andrx Labs, Llc |
Diltiazem controlled release formulation and method of manufacture
|
US20070128281A1
(en)
*
|
2005-12-02 |
2007-06-07 |
Patel Hasmukh B |
Oral osmotic drug delivery system
|
US20070128283A1
(en)
*
|
2005-12-02 |
2007-06-07 |
Patel Hasmukh B |
Oral osmotic drug delivery system
|
US20070128280A1
(en)
*
|
2005-12-02 |
2007-06-07 |
Patel Hasmukh B |
Oral osmotic drug delivery system
|
US20070128282A1
(en)
*
|
2005-12-02 |
2007-06-07 |
Patel Hasmukh B |
Oral osmotic drug delivery system
|
US8747897B2
(en)
|
2006-04-27 |
2014-06-10 |
Supernus Pharmaceuticals, Inc. |
Osmotic drug delivery system
|
US7419684B2
(en)
*
|
2006-12-22 |
2008-09-02 |
Reliant Pharmaceuticals, Inc. |
System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same
|
US7714201B2
(en)
*
|
2006-12-22 |
2010-05-11 |
Monsanto Technology Llc |
Cotton variety 781000G
|
DE102007011485A1
(de)
*
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
BRPI0906467C1
(pt)
*
|
2008-01-25 |
2021-05-25 |
Gruenenthal Gmbh |
forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
|
LT2273983T
(lt)
*
|
2008-05-09 |
2016-10-25 |
Grünenthal GmbH |
Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija
|
TW201105316A
(en)
*
|
2009-07-22 |
2011-02-16 |
Gruenenthal Gmbh |
Hot-melt extruded pharmaceutical dosage form
|
KR101747156B1
(ko)
|
2009-07-22 |
2017-06-27 |
그뤼넨탈 게엠베하 |
산화-안정화된 탬퍼-내성 용량형
|
CN102821757B
(zh)
*
|
2010-02-03 |
2016-01-20 |
格吕伦塔尔有限公司 |
通过挤出机制备粉末状药物组合物
|
MX2013002377A
(es)
|
2010-09-02 |
2013-04-29 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
|
RU2607499C2
(ru)
|
2010-09-02 |
2017-01-10 |
Грюненталь Гмбх |
Устойчивая к разрушению лекарственная форма, которая содержит анионный полимер
|
DE102011007272A1
(de)
|
2011-04-13 |
2012-10-18 |
Bayer Pharma Aktiengesellschaft |
Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
|
EA201400172A1
(ru)
|
2011-07-29 |
2014-06-30 |
Грюненталь Гмбх |
Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
|
EA201400173A1
(ru)
|
2011-07-29 |
2014-06-30 |
Грюненталь Гмбх |
Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
JP6117249B2
(ja)
|
2012-02-28 |
2017-04-19 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
|
JP6282261B2
(ja)
|
2012-04-18 |
2018-02-21 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
不正使用防止および過量放出防止医薬剤形
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
AU2014273227B2
(en)
|
2013-05-29 |
2019-08-15 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing one or more particles
|
AR096439A1
(es)
|
2013-05-29 |
2015-12-30 |
Gruenenthal Gmbh |
Forma de dosificación resistente al uso indebido que contiene una o más partículas
|
CA2914365C
(fr)
|
2013-06-05 |
2022-03-15 |
Synchroneuron, Inc. |
Formulations d'acamprosate, procedes d'utilisation de celles-ci, et combinaisons comprenant celles-ci
|
CA2917136C
(fr)
|
2013-07-12 |
2022-05-31 |
Grunenthal Gmbh |
Forme posologique inviolable contenant un polymere d'ethylene-acetate de vinyle
|
JP6480936B2
(ja)
|
2013-11-26 |
2019-03-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
クライオミリングによる粉末状医薬組成物の調製
|
AU2015261060A1
(en)
|
2014-05-12 |
2016-11-03 |
Grunenthal Gmbh |
Tamper resistant immediate release capsule formulation comprising Tapentadol
|
EA201692388A1
(ru)
|
2014-05-26 |
2017-05-31 |
Грюненталь Гмбх |
Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
|
WO2016132217A1
(fr)
|
2015-02-20 |
2016-08-25 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Procédé d'amélioration de la thérapie par agoniste du récepteur gaba-b
|
MX2017013637A
(es)
|
2015-04-24 |
2018-03-08 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
|
CA2998259A1
(fr)
|
2015-09-10 |
2017-03-16 |
Grunenthal Gmbh |
Protection contre un surdosage par voie orale a l'aide de formulations a liberation immediate dissuasives d'abus
|
CN112469398A
(zh)
|
2018-07-24 |
2021-03-09 |
拜耳公司 |
可口服给药并具有缓释作用的药物剂型
|
US10905667B2
(en)
|
2018-07-24 |
2021-02-02 |
Bayer Pharma Aktiengesellschaft |
Orally administrable modified-release pharmaceutical dosage form
|
JOP20210019A1
(ar)
|
2018-07-24 |
2021-01-24 |
Bayer Ag |
شكل جرعة صيدلانية تعطى عن طريق الفم ذات اطلاق مُعدّل
|
EP4245300A4
(fr)
*
|
2022-01-31 |
2024-04-24 |
Sumitomo Seika Chemicals Co., Ltd. |
Composition de préparation à libération contrôlée de médicament et préparation à libération contrôlée de médicament
|